Phase I study pilot arms of radiotherapy and carmustine with temozolomide for anaplastic astrocytoma (Radiation Therapy Oncology Group 9813): Implications for studies testing initial treatment of brain tumors

International Journal of Radiation Oncology Biology Physics

Volumn 59, Issue 4, 2004, Pages 1122-1126

  Chang, Susan M ^a   Seiferheld, Wendy ^b   Curran, Walter ^c   Share, R ^d   Atkins, J ^e   Choucair, Ali ^f   Kresl, J ^g   Thoron, Louisa ^h   Cairncross, Gregory ⁱ   Gilbert, Mark ^j   Bahary, Jean Paul ^k   Dolinskas, Carol ^l   Louis, David N ^m   Bushunow, Peter ⁿ   Buckner, Jan ^o   Barger, Geoffrey ^p   Mehta, Minesh ^q  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b RTOG Headquarters   (United States)

^c THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

^d Ingalls Memorial Hospital   (United States)

^e Southeastern Medical Oncology Center   (United States)

^f LDS HOSPITAL   (United States)

^g ST JOSEPH'S HOSPITAL AND MEDICAL CENTER   (United States)

^h WILLS EYE HOSPITAL   (United States)

ⁱ UNIVERSITY OF CALGARY   (Canada)

^j UNIVERSITY OF TEXAS   (United States)

^k CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^l PENNSYLVANIA HOSPITAL   (United States)

^m MASSACHUSETTS GENERAL HOSPITAL   (United States)

ⁿ ROCHESTER GENERAL HOSPITAL   (United States)

^o MAYO CLINIC   (United States)

^p WAYNE STATE UNIVERSITY   (United States)

^q University of Wisconsin Health   (United States)

more..

Author keywords

Anaplastic astrocytoma; Carmustine; Radiotherapy; Temozolomide

Indexed keywords

BRAIN; PATIENT TREATMENT; RADIOTHERAPY; TOXICITY; TUMORS;

ASTROCYTOMA; BRAIN TUMORS;

ONCOLOGY;

CARMUSTINE; TEMOZOLOMIDE;

ADULT; ARTICLE; BLOOD TOXICITY; BONE MARROW TOXICITY; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; EMBOLISM; FEBRILE NEUTROPENIA; FEMALE; GLIOBLASTOMA; HUMAN; INFECTION; INFORMED CONSENT; LUNG FUNCTION TEST; LUNG TOXICITY; MALE; METABOLIC SYNDROME X; NEUROTOXICITY; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; SIDE EFFECT; SKIN TOXICITY; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT WITHDRAWAL; VERTIGO;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASTROCYTOMA; BRAIN NEOPLASMS; CARMUSTINE; DACARBAZINE; FEMALE; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS;

EID: 3042561448     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2004.01.002     Document Type: Article

References (18)

1. Leibel S.A., Scott C.B., Loeffler J.S. Contemporary approaches to the treatment of malignant gliomas with radiation therapy. Semin Oncol. 21:1994;198-219
2. Chang S., Theodosopoulos P., Sneed P. Multidisciplinary management of adult anaplastic astrocytomas. Semin Radiat Oncol. 11:2001;163-169
3. Prados M.D., Scott C., Curran W.J. Jr, et al. Procarbazine, lomustine, and vincristine (PCV) chemotherapy for anaplastic astrocytoma A retrospective review of Radiation Therapy Oncology Group protocols comparing survival with carmustine or PCV adjuvant chemotherapy. J Clin Oncol. 17:1999;3389-3395
4. Chemotherapy for high-grade glioma. Cochrane Database Syst Rev 2002:CD003913
5. Friedman H.S., Dolan M.E., Pegg A.E., et al. Activity of temozolomide in the treatment of central nervous system tumor xenografts. Cancer Res. 55:1995;2853-2857
6. O'Reilly S.M., Newlands E.S., Glaser M.G., et al. Temozolomide A new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumours. Eur J Cancer. 29A:1993;940-942
7. Plowman J., Waud W.R., Koutsoukos A.D., et al. Preclinical antitumor activity of temozolomide in mice efficacy against human brain tumor xenografts and synergism with 1, 3-bis(2-chloroethyl)-1-nitrosourea. Cancer Res. 54:1994;3793-3799
8. Stevens M.F., Newlands E.S. From triazines and triazenes to temozolomide. Eur J Cancer. 29A:1993;1045-1047
9. Yung W.K., Prados M.D., Yaya-Tur R., et al. Temodal Brain Tumor Group. J Clin Oncol. 17:1999;2762-2771
10. Newlands E.S., O'Reilly S.M., Glaser M.G., et al. The Charing Cross Hospital experience with temozolomide in patients with gliomas. Eur J Cancer. 32A:1996;2236-2241
11. Bower M., Newlands E.S., Bleehen N.M., et al. Multicentre CRC phase II trial of temozolomide in recurrent or progressive high-grade glioma. Cancer Chemother Pharmacol. 40:1997;484-488
12. Schold S.C. Jr, Kuhn J.G., Chang S.M., et al. A phase I trial of 1, 3-bis(2-chloroethyl)-1-nitrosourea plus temozolomide A North American Brain Tumor Consortium study. Neuro-oncol. 2:2000;34-39
13. Hammond L., Kuhn J., Rizzo J., et al. A phase 1 and pharmacokinetic trial of 2 sequences of BCNU and temozolomide in patients with advanced solid tumors. [Abstract] Neuro-oncol. 2:2000;267
14. Chang S.M., Kuhn J.G., Rizzo J., et al. Phase I study of paclitaxel in patients with recurrent malignant glioma A North American Brain Tumor Consortium report. J Clin Oncol. 16:1998;2188-2194
15. Sargent D.J., Chan V., Goldberg R.M. A three-outcome design for phase II clinical trials. Control Clin Trials. 22:2001;117-125
16. Bryant J., Day R. Incorporating toxicity considerations into the design of two-stage phase II clinical trials. Biometrics. 51:1995;1372-1383
17. Quinn JA, Pluda J, Dolan ME, et al. Phase II trial of carmustine plus O(6)-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma. J Clin Oncol 2002;20:2277-2283
18. Friedman H.S., Pluda J., Quinn J.A., et al. Phase I trial of carmustine plus O6-benzylguanine for patients with recurrent or progressive malignant glioma. J Clin Oncol. 18:2000;3522-3528